Drug Trial Radar · NCT07916961
Study of AB-110 in Healthy and Hypertensive Participants
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Antlia Bioscience, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI \> 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety. The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety, the study is designed to enable insights on secondary and exploratory research questions, including Blood Pressure (BP) reduction and exploratory biomarkers.
Conditions
- Hypertension (HTN)
- Healthy Adult Participants
Interventions
Active drugDrug
AB-110 will be administered by subcutaneous (SC) injection
AB-110 Matching PlaceboDrug
Placebo doses will be administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events and Serious Adverse Events, overall, by severity and relationship to AB-110/placeboTime frame: Part A: From baseline up to Day 21; Part B: From baseline up to Day 36
- Incidence of injection site reactionsTime frame: Part A: From baseline up to Day 21; Part B: From baseline up to Day 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.